Branded Legacy Advances FDA Pathway for Low-Cost Intranasal Naloxone Alternative

Branded Legacy, Inc. (OTC: BLEG) has announced that its subsidiary, BioLegacy Evaluative Group, has initiated preparation of its FDA Pre-Abbreviated New Drug Application briefing package for a proprietary intranasal naloxone spray. This development represents a significant step toward providing a cost-effective alternative to existing opioid overdose reversal medications currently on the market.

The company's submission includes comprehensive documentation required for FDA review, including a Target Product Profile for both 2 mg and 4 mg naloxone HCl nasal sprays, detailed Chemistry, Manufacturing and Controls specifications, a 60-subject bioequivalence study comparing the product to Narcan, and human factors testing designed to ensure the product can be effectively used by non-medical personnel during emergency situations.

Kristian Thorlund, Executive Chair of Branded Legacy, emphasized the importance of the company's approach, stating that their intranasal platform aims to replicate Narcan performance while significantly reducing cost and improving global accessibility. This development comes at a critical time as communities worldwide continue to grapple with the devastating effects of the opioid crisis.

The company's progress follows BioLegacy's provisional patent filing for its air-driven delivery platform, which is designed specifically to offer a scalable solution to address the ongoing opioid overdose crisis. The timing of this advancement is particularly relevant given the increasing demand for affordable overdose reversal medications across multiple markets and healthcare systems.

For additional information about the company and its initiatives, visit https://BrandedLegacy.com. The broader implications of this development extend beyond immediate medical applications, potentially influencing public health policy and emergency response protocols in communities affected by opioid misuse.

The preparation of the Pre-ANDA briefing package represents a crucial regulatory milestone that could accelerate the availability of alternative naloxone delivery systems. As the opioid crisis continues to evolve, innovations in drug delivery technology and cost reduction strategies become increasingly important for expanding access to life-saving interventions.

This advancement in intranasal naloxone technology addresses multiple challenges simultaneously, including cost barriers that have limited widespread distribution of existing products. The company's focus on both performance equivalence and affordability could potentially transform how emergency overdose response is managed in various settings, from healthcare facilities to community-based harm reduction programs.